Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina, talks about how there might be a link between obstructive sleep apnea (OSA) and Alzheimer disease (AD), and that treating sleep apnea early and aggressively may help prevent AD development.
Alzheimer disease, obstructive sleep apnea (OSA), and mild cognitive impairment (MCI) likely have a bidirectional relationship, emphasizing the need for early and aggressive treatment of OSA, said Chitra Lal, MD, D-ABSM, FCCP, FAASM, FACP, ATSF, professor of medicine at Medical University of South Carolina.
Lal presented findings on Sunday at the at the 2023 American Thoracic Society International Conference, with simultaneous publication in Annals of the American Thoracic Society.
Transcript
What is the relationship between OSA, Alzheimer disease, and MCI?
The relationship between obstructive sleep apnea, mild cognitive impairment, and Alzheimer disease is likely bidirectional. It's a complex bidirectional causal relationship, but currently we don't have enough data to prove that. Having said that, obstructive sleep apnea has been associated with mild cognitive impairment; about 1 out of 4 OSA patients will have some degree of cognitive deficits.
OSA is also very common in Alzheimer disease, and we know that mild cognitive impairment progresses to Alzheimer disease at the rate of about 10 to 15 persons per year. So, it's very possible that obstructive sleep apnea is a modifiable risk factor for Alzheimer disease, and treating OSA early and aggressively might prevent the development of Alzheimer disease as a downstream effect.
Alzheimer disease in itself can possibly also worsen sleep apnea because it impacts breathing through complex neurological mechanisms. But again, we don't have enough data to support a bidirectional causal relationship but there's strong biological plausibility that it is a bidirectional relationship.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More